February 12, 2018 / 6:09 AM / 9 days ago

BRIEF-Roche says Phase II study shows potential for new eye drug

Feb 12 (Reuters) - Roche Holding Ag:

* SAYS PHASE II DATA SUPPORT POTENTIAL FOR ROCHE’S NOVEL ANTI-VEGF/ANTI-ANGIOPOIETIN-2 BISPECIFIC ANTIBODY FOR PEOPLE WITH DIABETIC MACULAR EDEMA‍​

* SAYS RG7716 DEMONSTRATED CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT IMPROVEMENTS IN VISUAL ACUITY Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below